Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia. [electronic resource]
Producer: 20180910Description: 1764-1766 p. digitalISSN:- 1029-2403
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Female
- Hepatitis B -- complications
- Hepatitis B virus -- drug effects
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- complications
- Male
- Middle Aged
- Protein Kinase Inhibitors -- adverse effects
- Risk Assessment
- Virus Activation -- drug effects
- Young Adult
No physical items for this record
Publication Type: Letter
There are no comments on this title.
Log in to your account to post a comment.